{"entity":{"id":"nct07060989","kind":"trial","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","aka":[],"tldr":"A phase 1/2 trial of NTS071 in advanced solid tumours, run by Nutshell Therapeutics (Shanghai) Co., LTD., now recruiting.","summary":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation is a phase 1/2 interventional study registered as NCT07060989 by Nutshell Therapeutics (Shanghai) Co., LTD., with 220 participants planned, started 2025-08-04 and due to reach its primary completion in 2028-12. Interventions recorded: NTS071.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07060989","url":"https://clinicaltrials.gov/study/NCT07060989"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07060989","phase":"1/2","setting":"A Phase 1/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","sponsor":"Nutshell Therapeutics (Shanghai) Co., LTD.","enrolled":220,"outcomes":[]},"route":"/trials/nct07060989/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}